Smith & Nephew nudges up guidance and unveils new strategic plan

Smith & Nephew unveiled a new RISE strategy and set 2028 targets of 6–7% CAGR revenue, 9–10% trading profit growth and over $1bn in free cash flow, while tightening 2025 guidance to ~5.8% underlying revenue growth, trading profit margin of at least 19.5% and raising 2025 free cash flow guidance to ~$800m. The company flagged a one-off non‑cash provision of ~ $200m in 2025 to support portfolio rationalisation (aimed at reducing gross inventory by ~$500m) and expects ~6% underlying revenue growth and another ~$800m free cash flow in 2026; Capital Markets Day events on Dec 8/11 will present further detail.

Analysis

Market structure: Smith & Nephew (SNN) strengthening margins and guiding $800m FCF in 2025 with 6–7% revenue CAGR to 2028 shifts payoff to cash-generative med‑tech names. Winners: SNN, suppliers with scale and high-margin implant franchises; losers: smaller pure‑play orthopaedics and regional distributors facing inventory rationalisation and one‑off charges. Currency exposure matters — guidance is “based on current exchange rates”, so a sustained USD/GBP move >3% will materially swing reported growth.

Risk assessment: Tail risks include execution failure on portfolio rationalisation (inventory write‑downs >$200m), regulatory setbacks on implants, or a cyclical slowdown in elective surgeries that could erase margin gains. Immediate risk window is the Capital Markets Days (Dec 8/11) and 30‑90 days post‑presentation for management detail; medium term (6–18 months) centres on inventory reduction delivery and FCF conversion; long term is delivery against 2028 targets. Hidden dependency: margin targets assume reinvestment and M&A discipline — aggressive bolt‑ons could dilute returns.

Trade implications: Tactical long SNN exposure for 6–12 months to capture margin upside and cash conversion, sized 1–3% of portfolio; use call spreads to finance upside if IV is rich. Consider a relative play long SNN vs short ZBH/SYK if you believe SNN’s inventory-led gross margin recovery will outpace peers. Fixed income: tighten credit view — SNN bonds should benefit if FCF >$800m is sustained; monitor CDS tightening >10bp as a buy signal.

Contrarian angles: Consensus may underprice execution risk of rationalisation and overprice structural improvement; the $200m non‑cash charge signals potential legacy product or obsolescence issues that can recur. If inventory reduction is achieved too fast it could tighten supply and depress near‑term revenue, creating a 3–6 month sell‑the‑news opportunity. Historical parallel: prior multi‑year turnaround plans in med‑tech often took 12–24 months to fully translate into EPS, so patience and tranche sizing matter.

Key Decisions for Investors

• Establish a 2–3% long position in SNN (LSE:SNN) with a 6–12 month horizon to capture margin expansion and $800m+ FCF; set risk triggers to trim/stop if FY25 FCF guidance falls below $700m or trading margin guidance drops under 19.0%.
• If implied volatility is elevated, buy a 9–15 month call spread on SNN: long 5% OTM call, short 15% OTM call, sizing c.0.5–1.0% of portfolio to limit premium while retaining upside to the 2026 guidance cadence.
• Implement a pair trade: long SNN (1.5%) vs short ZBH (1.5%) for 6–12 months to exploit expected relative margin/F CF outperformance; unwind if SNN underperforms peer by >5% absolute or misses FCF target by >10%.
• Reweight healthcare: increase exposure to high‑FCF large‑cap medtech (SNN, SYK) by +2–4% aggregate over next 4–8 weeks and reduce small pure‑play orthopaedic/surgical names by equivalent amount; reassess after Capital Markets Day detail and H1 2026 inventory metrics (target: gross inventory reduction ≥$300m by mid‑2026).